Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14935590 | 0.84 | LMNA (0.40) | PIK3CDPIK3CGPIK3R1 | |
| SCHEMBL29853404 | 0.76 | GALR3 (0.62) | — | |
| SCHEMBL6268307 | 0.76 | GALR3 (0.62) | — | |
| SCHEMBL14947683 | 0.76 | PLK1 (0.44) | PIK3CDPIK3R1 | |
| SCHEMBL18878391 | 0.70 | GRM4 (0.45) | — | |
| SCHEMBL14947692 | 0.68 | GRM4 (0.43) | — | |
| SCHEMBL14947693 | 0.68 | GRM4 (0.43) | — | |
| SCHEMBL17040353 | 0.68 | RAB9A (0.44) | — | |
| SCHEMBL1815838 | 0.68 | HPGDS (0.55) | — | |
| SCHEMBL20282465 | 0.66 | CFTR (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123281-A1 | Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules | BETA CAT PHARMACEUTICALS, LLC (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123281-A1 | Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules | BETA CAT PHARMACEUTICALS, LLC (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2013071232-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF TBL-1 BINDING TO DISEASE-ASSOCIATED MOLECULES | BETA CAT PHARMACEUTICALS, LLC (US) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123281-A1 | Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules | TBL2, TBL3, TBL1XR1 | PIK3CD 2228/4885PIK3CG 1694/4885PIK3R1 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.